AlphAIAlphAI — Financial news for AI agents
fool.comOCT 293 min read$LLY

Eli Lilly (LLY) Q3 2026 Earnings Call Transcript

Eli Lilly (LLY) reported Q3 2026 revenue of $24.4B, up 39% YoY, driven by Mounjaro and Zepbound. Non-GAAP EPS was $7.48. FY 2026 guidance raised to $91B-$92B. Key growth areas include obesity and diabetes treatments, with strong international demand. The company invested in manufacturing and R&D, facing pricing pressures offset by volume growth.

Original reporting
fool.com
Published Oct 29, 2026, 7:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Eli Lilly (LLY) Q3 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The earnings beat and guidance raise expectations for the stock, though margin pressure from pricing and large capex could temper enthusiasm.

02

Market read

Earnings beat and guidance lift LLY, with spillover to the broader healthcare sector.

03

What to watch

One‑time $410M milestone and $11.5B capex may strain cash flow in the near term.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Eli Lilly reported its Q3 2026 results, highlighting rapid growth in its obesity and diabetes franchises and raising full‑year guidance.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Q3 2026 earnings release with $24.4B revenue, 39% YoY growth and raised FY guidance to $91-92B.

Expected impact

potential upside as revenue beat offsets pricing headwinds

Evidence & confidence

First report of earnings and guidance for a large-cap pharma; material numbers and guidance raise expectations.

Market effects

Sector

Weight‑loss and diabetes market outlook improves, boosting peers in the incretin space.

Regional

Strong China performance may lift Asian pharma sentiment.

Global

Large‑cap pharma earnings influence broader market risk appetite.

Counterpoint

What could challenge this read

Pricing pressure could erode margins, leading to a pullback despite revenue growth.

Key entities

  • company
    Eli Lilly and Company

    Pharmaceutical company reporting Q3 earnings.

Read at source← All news

StoryEli Lilly beats Q3 earnings, lifts full‑year revenue outlook and trims EPS guidance

Also covered by

4 outlets

Related articles

OCT 29
$GOOGLMedAI 8/10

Alphabet's AI Spending Shock Drags Nasdaq Down 1.7% as Wall Street's Big Three Retreat

Alphabet's shares fell 13.2% after its quarterly report missed revenue forecasts and showed increased AI spending, dragging the Nasdaq down 1.7%. The S&P 500 and Dow Jones also declined. Investors are differentiating between companies funding AI internally and those relying on debt or cash burn. Other notable movers include Caterpillar (-9.5%), Fortinet (-20%), and Eli Lilly (+6.3%).

finance.biggo.com6 min
OCT 29
$LLYHighAI 9/10

Lilly Raises 2026 Revenue Outlook as Mounjaro, Zepbound Sales Rise

Eli Lilly raised its 2026 revenue outlook to $91B-$92B due to strong sales of Mounjaro and Zepbound, reporting Q3 revenue of $24.4B, up 38% YoY. Mounjaro revenue grew 65% to $10.7B, while Zepbound grew 49% to $5.35B. Non-GAAP EPS was $7.48, up 7% YoY. Lilly cited acquisition-related charges for a slight EPS forecast reduction.

econotimes.com5 min
OCT 29
$LLYMedAI 8/10

Eli Lilly and Company Q3 2026 Earnings Call Summary

Eli Lilly reported Q3 2026 revenue growth of 39%, driven by Mounjaro, Zepbound, and oncology/immunology/neuroscience portfolios. Full-year guidance raised to $91-$92B. Management highlighted Medicare GLP-1 bridge program success, international expansion, and investments in manufacturing and R&D. Non-recurring items added $900M to Q3 revenue, with $2B expected for 2026. Strategic shifts include global market restructuring and pipeline advancements in Alzheimer's and obesity treatments.

finance.yahoo.com7 min
OCT 29
$LLYHighAI 9/10

Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reaction

Eli Lilly (LLY) reported Q3 revenue of $24.4B, up 39% YoY, driven by 53% volume growth despite a 15% price drop. Shares rose 6% midday. Management raised 2026 revenue guidance to $91B-$92B. Gross margin increased to 83.9%, and GAAP EPS rose 16% to $7.22. Growth was fueled by Mounjaro and Zepbound, which generated two-thirds of revenue.

finance.yahoo.com2 min